Loading
Lab-grown mini-tumours are already being sold to guide treatment, but the tests are not validated like other medical tests. They should be.
Functional drug-response assays are entering clinical use without the analytical validation (precision, repeatability, reference ranges, failure rate reporting) or clinical validation (prospective outcome correlation) required of companion diagnostics. The proposal is a formal assay validation framework, developed with regulators, defining minimum performance, standardised reporting of derivation success rate, and mandatory registry submission of predictions and outcomes.
Shares Curesponse, Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Curesponse, SEngine Precision Medicine, Xilis, Ex vivo drug sensitivity screening in blood cancers (EXALT).
Shares Xilis, Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Curesponse, SEngine Precision Medicine, Xilis, Functional (ex vivo) drug testing.
Shares Estimation of clinical trial success rates and related parameters, Preclinical results do not reproduce, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Preclinical results do not reproduce, Patient-derived organoids, Lab models that fail to predict what happens in patients.